{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:40:14Z","timestamp":1777660814558,"version":"3.51.4"},"reference-count":33,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Genetic Testing and Molecular Biomarkers"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      There is extensive interindividual variability in response and tolerance to anticancer drugs. This heterogeneity provides a major limitation to the \u201crational\u201d use of cytotoxic drugs, and it becomes a major problem in oncology giving a narrow therapeutic window with a vital risk. Among these anticancer drugs, irinotecan can cause dose-limiting toxicities, commonly diarrhea and neutropenia. Interaction among pathways of activation\/inactivation (\n                      <jats:italic toggle=\"yes\">UGT1A1<\/jats:italic>\n                      ) and hepatobiliary transport of irinotecan and its metabolites could, in part, explain its interindividual variability. The objective of this study was to perform an exploratory analysis to evaluate the correlation between the genetic polymorphisms of\n                      <jats:italic toggle=\"yes\">UGT1A1<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">ABCC2<\/jats:italic>\n                      with the different toxicities associated with irinotecan treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Seventy-five patients with solid cancers were included, all were administered an irinotecan-based regimen in both Mission Bay Medical Center; and Zuckerberg San Francisco General Hospital from May 2016 to December 2016. The patients' genotyping was performed for both the\n                      <jats:italic toggle=\"yes\">UGT1A1<\/jats:italic>\n                      *28 polymorphism, and the\n                      <jats:italic toggle=\"yes\">ABCC2<\/jats:italic>\n                      \u2009\u2212\u20091549G&gt;A, and\n                      <jats:italic toggle=\"yes\">ABCC2<\/jats:italic>\n                      \u2009\u2212\u20091249G&gt;A single nucleotide polymorphism. Comparisons among qualitative data were assessed using the \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      -test, and Fisher's exact test in the case of small group sizes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Diarrhea was observed in 40 patients (53.3%), among them only 9 patients had high grades diarrhea (grades III and IV). Grades III\/IV of nausea were more frequently associated with the\n                      <jats:italic toggle=\"yes\">ABCC2<\/jats:italic>\n                      -1549 AA genotype (83.3%\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.004) in patients with colorectal cancer. In pancreatic cancer, a significant absence of diarrhea grades III-IV was noted in patients with the\n                      <jats:italic toggle=\"yes\">ABCC2<\/jats:italic>\n                      1249 GG genotype compared to the other\n                      <jats:italic toggle=\"yes\">ABCC2<\/jats:italic>\n                      1249 genotypes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/gtmb.2022.0109","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T17:00:38Z","timestamp":1685552438000},"page":"133-141","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictive Value of\n                    <i>ABCC2<\/i>\n                    and\n                    <i>UGT1A1<\/i>\n                    Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5137-0595","authenticated-orcid":false,"given":"Zineb","family":"Aoullay","sequence":"first","affiliation":[{"name":"Department of Sciences du M\u00e9dicament, Laboratory of Pharmacology and Toxicology, Faculty of Medicine and Pharmacy of Rabat, University Mohamed V Rabat, Rabat, Morocco."},{"name":"Department of Laboratory Medicine, University of California San Francisco and Zuckerberg San Francisco General Hospital, San Francisco, California, USA."},{"name":"Institut de Recherche sur le Cancer-IRC, Fes, Morocco."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California San Francisco and Zuckerberg San Francisco General Hospital, San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meriem","family":"Slaoui","sequence":"additional","affiliation":[{"name":"Research Team in Tumour Pathology, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Morocco."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihssane","family":"El Bouchikhi","sequence":"additional","affiliation":[{"name":"Medical Genetics and Oncogenetics Laboratory, Hassan II University Hospital, Fez, Morocco."},{"name":"Multidisciplanary Laboratory for Research &amp; Innovation, GBG Department, Polydisciplinary Faculty of Khouribga, Sultan Moulay Slimane University, Khouribga, Morocco."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Ghazal","sequence":"additional","affiliation":[{"name":"Department of Fundamental Sciences, School of Medicine, Mohammed VI University of Health Sciences, Casablanca, Morocco."},{"name":"National Center for Scientific and Technical Research, Rabat, Morocco."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najib","family":"Al Idrissi","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Mohammed VI University of Health Sciences, Casablanca, Morocco."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouchra","family":"Meddah","sequence":"additional","affiliation":[{"name":"Department of Sciences du M\u00e9dicament, Laboratory of Pharmacology and Toxicology, Faculty of Medicine and Pharmacy of Rabat, University Mohamed V Rabat, Rabat, Morocco."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara L.","family":"Lynch","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California San Francisco and Zuckerberg San Francisco General Hospital, San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahia","family":"Cherrah","sequence":"additional","affiliation":[{"name":"Department of Sciences du M\u00e9dicament, Laboratory of Pharmacology and Toxicology, Faculty of Medicine and Pharmacy of Rabat, University Mohamed V Rabat, Rabat, Morocco."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan H.B.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of California San Francisco and Zuckerberg San Francisco General Hospital, San Francisco, California, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"issue":"24","key":"e_1_3_5_2_1","first-page":"6921","article-title":"Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis","volume":"60","author":"Ando Y","year":"2000","unstructured":"Ando Y, , Saka H, , Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res, 2000; 60(24):6921-6926.","journal-title":"Cancer Res"},{"key":"e_1_3_5_3_1","doi-asserted-by":"crossref","unstructured":"Ando Y Saka H Asai G et al. UGT1A1 genotypes and glucuronidation of SN-38 the active metabolite of irinotecan. Ann Oncol 1998;9(8)845-847.","DOI":"10.1023\/A:1008438109725"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70351-0"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S137644"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13757"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.14.8170"},{"issue":"10","key":"e_1_3_5_8_1","first-page":"1934","article-title":"Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats","volume":"57","author":"Chu XY","year":"1997","unstructured":"Chu XY, , Kato Y, , Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res, 1997; 57(10):1934-1939.","journal-title":"Cancer Res"},{"issue":"22","key":"e_1_3_5_9_1","first-page":"5137","article-title":"Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters","volume":"58","author":"Chu XY","year":"1998","unstructured":"Chu XY, , Kato Y, , Ueda K, et al. Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters. Cancer Res, 1998; 58(22):5137-5143.","journal-title":"Cancer Res"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100019"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920011798062283"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02034-1"},{"key":"e_1_3_5_13_1","doi-asserted-by":"crossref","unstructured":"Ehmer U Lankisch TO Erichsen TJ Consultations in molecular diagnostics rapid allelic discrimination by TaqMan PCR for the detection of the Gilbert\u2019 s syndrome marker. J Mol Diagn 2008;10(6):549-552; doi: 10.2353\/jmoldx.2008.080036","DOI":"10.2353\/jmoldx.2008.080036"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.058"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.31.2137"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2010.10"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2011.533"},{"issue":"4","key":"e_1_3_5_18_1","first-page":"596","article-title":"Pharmacogenetics of anticancer agents: Lessons from amonafide and irinotecan","volume":"29","author":"Innocenti F","year":"2001","unstructured":"Innocenti F, , Iyer L, , Ratain MJ. Pharmacogenetics of anticancer agents: Lessons from amonafide and irinotecan. Drug Metab Dispos, 2001; 29(4 Pt 2):596-600.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.7.8.1211"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.173"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-005-6810-2"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200103000-00008"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500072"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.001800"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.24.18_suppl.13072"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3406-2"},{"issue":"8","key":"e_1_3_5_27_1","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"7","author":"Mathijssen RH","year":"2001","unstructured":"Mathijssen RH, , van Alphen RJ, , Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res, 2001; 7(8):2182-2194; doi: 10.1163\/156856001300248353","journal-title":"Clin Cancer Res"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.5850"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.7"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5356.1504"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5356.1534"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002800051078"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.5400"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf337"}],"container-title":["Genetic Testing and Molecular Biomarkers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/gtmb.2022.0109","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/gtmb.2022.0109","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/gtmb.2022.0109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:23:32Z","timestamp":1777447412000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/gtmb.2022.0109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1089\/gtmb.2022.0109"],"URL":"https:\/\/doi.org\/10.1089\/gtmb.2022.0109","relation":{},"ISSN":["1945-0265","1945-0257"],"issn-type":[{"value":"1945-0265","type":"print"},{"value":"1945-0257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}